Worsening of wilson disease following penicillamine therapy

European Neurology

Volumn 71, Issue 3-4, 2014, Pages 126-131

  Kalita, Jayantee ^a   Kumar, Vijay ^a   Chandra, Satish ^a   Kumar, Bishwanath ^a   Misra, Usha Kant ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Chronic liver disease; Copper; Leukopenia; Pancytopenia; Penicillamine; Wilson disease; Worsening of Wilson disease

Indexed keywords

PENICILLAMINE; ZINC; ZINC ACETATE; BENZODIAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT;

ADOLESCENT; ARTICLE; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DETERIORATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPERSALIVATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SIBLING; SPLENOMEGALY; THROMBOCYTOPENIA; ULTRASOUND; WILSON DISEASE; CLINICAL LABORATORY; DISEASE SEVERITY; DYSTONIA; ECHOGRAPHY; MENTAL DETERIORATION; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; CHELATING AGENTS; CHILD; FEMALE; HEPATOLENTICULAR DEGENERATION; HUMANS; MALE; PENICILLAMINE; TREATMENT OUTCOME;

EID: 84897411951     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000355276     Document Type: Article

References (24)

1. Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW: The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 1993; 5: 327-337.
2. Scheinberg IH, Sternlieb I: Wilson's disease; in Smith LH Jr (ed): Major Problems in Internal Medicine. XXIII. Philadelphia, Saunders, 1984, vol 23, pp 126-155.
3. Brewer GJ, Terry CA, Aisen AM, Hill GM: Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch Neurol 1987; 44: 490-493.
4. Walshe JM: Penicillamine, a new oral therapy for Wilson's disease. Am J Med 1956; 21: 487-495.
5. Walshe JM: Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. Lancet 1982; 1: 643-647.
6. Mills CF, El-Gallad TT, Bremner I: Effects of molybdate, sulfide, and tetrathiomolybdate on copper metabolism in rats. J Inorg Biochem 1981; 14: 189-207.
7. Brewer GJ, Dick RD, Yuzbasiyan-Gurkin V, Tankanow R, Young AB, Kluin KJ: Initial therapy of patients with Wilson's disease with tetrathiomolybdate. Arch Neurol 1991; 48: 42-47.
8. Jones HB, Gooneratne SR, Howel JM: X-ray microanalysis of liver and kidney in copperloaded sheep with and without thiomolybdate administration. Res Vet Sci 1984; 37: 273.
9. Krystkowiak P, du Montcel ST, Vercueil L, Houeto JL, Lagrange C, Cornu P, Blond S, Benabid AL, Pollak P, Vidailhet M, SPIDY Group: Reliability of the Burke-Fahn-Marsden scale in a multicenter trial for dystonia. Mov Disord 2007; 22: 685-689.
10. Fahn S: Assessment of primary dystonia; in Munset TL (ed): Quantification of Neurologic Deficit. Boston, Butterworth, 1989, pp 241- 270.
11. Misra UK, Kalita J: Spectrum of movement disorders in encephalitis. J Neurol 2010; 257: 2052-2058.
12. Grimm G, Prayer L, Oder W, Ferenci P, et al: Comparison of functional and structural brain disturbances in Wilson's disease. Neurology 1991; 41: 272-276.
13. Medici V, Trevisan CP, D'Inca R, Barollo M, Zancan L, Fagiuoli S, et al: Diagnosis and management of Wilson's disease: results of a single center experience. J Clin Gastroenterol 2006; 40: 936-941.
14. Lange J: Long-term treatment of Wilson's disease with D -penicillamine. Report on 20 cases. Dtsch Med Wochenschr 1967; 92: 1657-1662.
15. Goldstein NP, Tauxe WN, McCall JT, et al: Wilson's disease (hepatolenticular degeneration). Treatment with penicillamine and changes in hepatic trapping of radioactive copper. Arch Neurol 1971; 24: 391-400.
16. Berry WR, Aronson AE, Darley FL, et al: Effects of penicillamine therapy and low-copper diet on dysarthria in Wilson's disease (hepatolenticular degeneration). Mayo Clin Proc 1974; 49: 405-408.
17. Arima M, Takeshita K, Yoshino K, et al: Prognosis of Wilson's disease in childhood. Eur J Pediatr 1977; 126: 147-154.
18. Czlonkowska A, Gajda J, Rodo M: Effects of long-term treatment in Wilson's disease with D -penicillamine and zinc sulphate. J Neurol 1996; 243: 269-273.
19. Giacchino R, Marazzi MG, Barabino A, Fasce L, Ciravegna B, Famularo L, et al: Syndromic variability of Wilson's disease in children. Clinical study of 44 cases. Ital J Gastroenterol Hepatol 1997; 29: 155-161.
20. Wiggelinkhuizen M, Tilanus ME, Bollen CW, Houwen RH: Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease. Aliment Pharmacol Ther 2009; 29: 947-958.
21. Durand F, Bernuau J, Giostra E, Mentha G, Shouval D, Degott C, et al: Wilson's disease with severe hepatic insufficiency: beneficial effects of early administration of D -penicillamine. Gut 2001; 48: 849-852.
22. Santos Silva EE, Sarles J, Buts JP, Sokal EM: Successful medical treatment of severely decompensated Wilson disease. J Pediatr 1996; 128: 285-287.
23. Brewer GJ, Askari F, Lorincz MT, Carlson M, Schilsky M, Kluin KJ, et al: Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol 2006; 63: 521-527.
24. Brewer GJ, Dick RD, Johnson VD, Brunberg JA, Kluin KJ, Fink JK: The treatment of Wilson's disease with zinc. XV. Long-term followup studies. J Lab Clin Med 1998; 132: 264-278.